Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | OSBP | P22059 | 1/20 | 0.68 |
| ▸ | RORC | P51449 | 1/20 | 0.68 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.68 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081070 | 1.00 | CYP46A1 (0.68) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL29081074 | 1.00 | CYP46A1 (0.68) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL29081076 | 1.00 | CYP46A1 (0.68) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL5935410 | 0.88 | GRIN1 (0.80) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL103515 | 0.88 | USP2 (0.74) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL2185461 | 0.88 | USP2 (0.74) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL4961477 | 0.88 | GRIN1 (0.80) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL932623 | 0.88 | USP2 (0.74) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL3508152 | 0.86 | CYP46A1 (0.71) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL18529717 | 0.86 | USP2 (0.71) | CYP46A1USP2LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116615202-A | 5 alpha-hydroxy-6 beta- [2- (1H-imidazol-4-yl) ethylamino ] -cholestan-3 beta-ol analogues for the treatment of cancer and pharmaceutical compositions comprising the same | 登德罗杰尼克斯公司 | 2023-08-18 | — | — | CN | disclosed |